Mobile UPI  |   About UPI  |   UPI en Español  |   UPI Arabic  |   UPIU  |   My Account
Search:
Go

Britain rejects arthritis drug

|
|
 
  
Published: Oct. 27, 2007 at 12:24 AM
Advertisement

LONDON, Oct. 27 (UPI) -- Britain's National Health Service has rejected the drug abatacept for severe arthritis sufferers because the cost is too high.

The National Institute for Clinical Effectiveness said the drug, marketed under the name Orencia, is effective but its price -- more than $19,000 per person per year -- is too expensive, The Independent said Friday.

Britain's National Rheumatoid Arthritis Society said 3,500 patients would qualify for the treatment.

"Whatever the price, we are talking about so few people who will now have nowhere else to go except back on to treatments which have already failed," said NRAS director Lynn Love.

© 2007 United Press International, Inc. All Rights Reserved. Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent.

Order reprints
  
Join the conversation
Most Popular Collections
The making of the Oscars The Chicago Auto Show 2011: The year in space
Mercedes-Benz fashion week In New York Tu Bishvat Migron settlement The Tibetan Moniam Festival in China
Additional Science News Stories
1 of 25
Meryl Streep and Colin Firth attend the "BAFTA" ceremony in London
View Caption
fark
McDonald's pushing farmers for a kinder McRib. Nope, you read that right
Nancy Grace screeches the appropriate question, "Who pushed Whitney Houston under water?"
Photoshop theme: Valentine's Day gifts, it's the thought that counts
Valentines your Mom got
Expect the Hoverboard to be in stores around October 21, 2015
If you say "I do not favor women wearing provocative clothes and always feel they need to be dignified...